China Now Registers More Clinical Studies Than the U.S. — While Western CROs Write Off $2.7 Billion of Backlog

The mechanisms are administrative, not exotic. China's clinical trial regulation requires ethics committees to issue an opinion within 30 days of accepting a submission, allows expedited reviews in 72 hours, and runs a 30-day trial review channel that commits sponsors to start the study within 12 weeks of approval. Rewritten Good Clinical Practice rules took effect on September 1, 2026, aligning every drug trial with ICH E6(R3). The result is a faster, cheaper readout, not a different standard of evidence.

Chinese contract research organizations are not nibbling at the growth. WuXi AppTec lifted nine-month revenue 38.6% to RMB45.54bn, grew continuing operations 46.3%, and carried a RMB76.74bn backlog up 36.4% into the fourth quarter — enough to raise full-year guidance to RMB61.0-61.9bn. Backlog grew faster than revenue at every Chinese CRO that disclosed it, which is what a cost curve reset looks like from inside the winners' books.

Trial volume is not shrinking; the price of holding it in a Western contract is. In the September quarter, IQVIA cut $2.1bn of contracted backlog after reviewing inactive trials, and Fortrea removed $558m for inactive studies and changed scope. Both said historical results and guidance were unaffected. The real signal is what a backlog is worth when a sponsor knows it can restart the same study at a fraction of the cost in China: contracted backlog stopped behaving like an asset.

The mechanism behind the write-downs is a reallocation, not a collapse. Cheap, fast trials let a Chinese sponsor generate global-grade data on a fraction of the budget, so it can run more shots on goal and license assets outward. Mainland Chinese innovators signed 157 out-licensing deals in 2025 with a potential value of RMB135.7bn and RMB7bn of upfronts; the first half of 2026 added RMB99.7bn of potential value; and NMPA data cited on September 14, 2026 put 2026 out-licensing above RMB120bn with upfronts above RMB10bn. Upfront payments in nine months of 2026 already exceeded the whole of 2025, which is what a repriced cost curve does to deal flow.

Both capitals are now managing the same arbitrage from opposite ends. On September 2, 2026 the FDA said it is expanding oversight of foreign trial sites, increasing the number of bioresearch monitoring inspectors at its China office and elsewhere, adding remote assessments and pre-submission discussions on the provenance of foreign data, and publishing deficiencies more openly. In August, Rep. John Moolenaar and Rep. Ben Cline asked Acting Commissioner Kyle Diamantas to decline China-generated clinical data for US applications unless the FDA had audited the site in person within the previous 12 months, citing three deaths in separate gene therapy trials run in China. Compliance cost is being added to the cheapest place to run a trial.

The first casualty of China's cheap, fast trials is not the trial itself and not the sponsor. It is the Western contract that turns a decade of development into a fixed fee. China's cost curve did not shrink the world's appetite for clinical data; it moved where that data is produced and who is paid for producing it, and the September-quarter write-downs at IQVIA and Fortrea are the first hard evidence thatthe fixed-fee clinical model is losing its pricing power at the same time.